INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Pregnancy, breast-feeding                          │ Pregnancy, breast-feeding                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who work for MATERIA MEDICA HOLDING (i.e. │ Patient works for OOO "NPF "MATERIA MEDICA         │      85 │
│ the company's employees, temporary contract        │ HOLDING" (i.e., is the company's employee,         │         │
│ workers, appointed officials responsible for       │ temporary contract worker or appointed official    │         │
│ carrying out the research or immediate relatives   │ responsible for carrying out the research or their │         │
│ of the aforementioned)                             │ immediate family)                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of functional dyspepsia established      │ Diagnosis of functional dyspepsia, based on the    │      86 │
│ according to Rome-IV criteria (2016)               │ Rome IV criteria (2016)                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Discontinuation of proton pump inhibitors,         │ Discontinuation of proton pump inhibitors,         │      92 │
│ prokinetics, antispasmodics, antacids, bismuth     │ propulsives, antispasmodics, antacids, or bismuth  │         │
│ preparations less than 7 days before randomization │ preparations less than 7 days prior to             │         │
│                                                    │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Availability of signed patient information sheet   │ Availability of a signed patient information sheet │      95 │
│ and informed consent form for participation in the │ (Informed Consent form) for participation in the   │         │
│ clinical trial                                     │ clinical trial                                     │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ History/suspicion of oncology of any location      │ Known history of/suspected malignant neoplasm of   │      47 │
│                                                    │ various sites                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severity of symptoms of dyspepsia ≥ 6 on the GIS   │ Diagnosis of functional dyspepsia, based on the    │      48 │
│ scale                                              │ Rome IV criteria (2016)                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 45 Years                  │ Men and women aged 18-45 years                     │      54 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Men and women aged 18-45 years                     │      57 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who gave their consent to use reliable    │ Patients who agree to use an effective method of   │      59 │
│ contraception during the study                     │ contraception throughout the clinical trial        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of drugs or alcohol (more than 2 alcohol units │ Drug addiction, alcohol use in the amount over 2   │      60 │
│ daily), presence of mental diseases                │ units of alcohol a day, mental diseases            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Negative test result for H. pylori infection       │ Negative H. pylori test                            │      63 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients of both genders aged 18-45 years old      │ Men and women aged 18-45 years                     │      64 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other severe comorbidity that, in the opinion  │ Other severe coexisting morbidity which, in the    │      66 │
│ of the investigator, may affect patient            │ investigator's opinion, can prevent the patient    │         │
│ participation in the clinical trial                │ from participating in the study                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Verified diagnosis of other functional GI          │ Diagnosis of other functional diseases of the      │      68 │
│ diseases, i.e. biliary dyskinesia, irritable bowel │ digestive system, such as dyskinesia of cystic     │         │
│ syndrome, etc                                      │ duct or gallbladder, irritable bowel syndrome, etc │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Allergy/intolerance intolerances to any of the     │ Allergy/intolerance to any of the components of    │      69 │
│ components of the study drugs                      │ medications used in the treatment                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any medications specified in the            │ Intake of medicines listed in the section          │      70 │
│ "Prohibited Concomitant Treatment" within 1 month  │ 'Prohibited concomitant treatment' for 1 month     │         │
│ prior to inclusion in the study                    │ prior to the enrollment in the trial               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in other clinical trials in the      │ Participation in other clinical trials within 3    │      71 │
│ previous 3 months                                  │ months to the enrollment in this study             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previously diagnosed cardiovascular diseases with  │ Prior diagnosis of a class IV cardiovascular       │      72 │
│ functional class IV (according to the              │ disease (according to the New York Heart           │         │
│ classification of the New-York Heart Association,  │ Association, 1964), hypothyroidism, diabetes       │         │
│ 1964), hypothyroidism, diabetes mellitus, chronic  │ mellitus, chronic kidney disease (С3-5), or        │         │
│ renal disease С3-5, hepatic diseases with portal   │ disease of liver with portal hypertension and/or   │         │
│ hypertension and/or signs of severe decompensation │ severe decompensation (Child-Pugh score > 6)       │         │
│ of function (\> 6 points according to the Child-   │                                                    │         │
│ Pugh classification)                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are related to any of the on-site     │ Patient is related to the research staff of the    │      72 │
│ research personnel directly involved in the        │ clinical investigative site who are directly       │         │
│ conduct of the trial or are an immediate relative  │ involved in the trial or is the immediate family   │         │
│ of the study investigator. 'Immediate relative'    │ member of the investigator. The immediate family   │         │
│ means husband, wife, parent, son, daughter,        │ members include husband/wife, parents, children or │         │
│ brother, or sister (regardless of whether they are │ brothers (or sisters), regardless of whether they  │         │
│ natural or adopted)                                │ are natural or adopted                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who, from the investigator's point of     │ Patients who, from investigator's point of view,   │      79 │
│ view, will not comply with the observation         │ will fail to comply with the observation           │         │
│ requirements of the study or adhere to study drug  │ requirements of the trial or with the dosing       │         │
│ dosing regimens                                    │ regimen of the investigational drugs               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ H. pylori eradication within 2 months prior to     │ H. Pylori eradication within 2 months before study │      80 │
│ enrollment                                         │ entry                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Organic diseases of the gastrointestinal tract     │ Organic diseases of the digestive system (gastro-  │      81 │
│ (gastroesophageal reflux disease (GERD), peptic    │ oesophageal reflux disease (GERD), ulcer, chronic  │         │
│ ulcer, chronic pancreatitis, cholelithiasis,       │ pancreatitis, cholelithiasis, fatty liver disease, │         │
│ hepatosis, hepatitis, hepatic cirrhosis, etc.)     │ hepatitis, cirrhosis of liver, etc.)               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intestinal infection within 2 months prior to      │ Intestinal infection within 2 months before study  │      81 │
│ enrollment                                         │ entry                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Scheduled hospitalization during the study for any │ Planned hospitalization during the study period,   │      84 │
│ diagnostic or therapeutic procedures               │ for any diagnostic or treatment procedures         │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                  │ GIS score of at least 6                            │      36 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History/suspicion of oncology of any location      │ Known history of/suspected malignant neoplasm of   │      47 │
│                                                    │ various sites                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who gave their consent to use reliable    │ Patients who agree to use an effective method of   │      59 │
│ contraception during the study                     │ contraception throughout the clinical trial        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of drugs or alcohol (more than 2 alcohol units │ Drug addiction, alcohol use in the amount over 2   │      60 │
│ daily), presence of mental diseases                │ units of alcohol a day, mental diseases            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Negative test result for H. pylori infection       │ Negative H. pylori test                            │      63 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients of both genders aged 18-45 years old      │ Men and women aged 18-45 years                     │      64 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other severe comorbidity that, in the opinion  │ Other severe coexisting morbidity which, in the    │      66 │
│ of the investigator, may affect patient            │ investigator's opinion, can prevent the patient    │         │
│ participation in the clinical trial                │ from participating in the study                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Verified diagnosis of other functional GI          │ Diagnosis of other functional diseases of the      │      68 │
│ diseases, i.e. biliary dyskinesia, irritable bowel │ digestive system, such as dyskinesia of cystic     │         │
│ syndrome, etc                                      │ duct or gallbladder, irritable bowel syndrome, etc │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Allergy/intolerance intolerances to any of the     │ Allergy/intolerance to any of the components of    │      69 │
│ components of the study drugs                      │ medications used in the treatment                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any medications specified in the            │ Intake of medicines listed in the section          │      70 │
│ "Prohibited Concomitant Treatment" within 1 month  │ 'Prohibited concomitant treatment' for 1 month     │         │
│ prior to inclusion in the study                    │ prior to the enrollment in the trial               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in other clinical trials in the      │ Participation in other clinical trials within 3    │      71 │
│ previous 3 months                                  │ months to the enrollment in this study             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previously diagnosed cardiovascular diseases with  │ Prior diagnosis of a class IV cardiovascular       │      72 │
│ functional class IV (according to the              │ disease (according to the New York Heart           │         │
│ classification of the New-York Heart Association,  │ Association, 1964), hypothyroidism, diabetes       │         │
│ 1964), hypothyroidism, diabetes mellitus, chronic  │ mellitus, chronic kidney disease (С3-5), or        │         │
│ renal disease С3-5, hepatic diseases with portal   │ disease of liver with portal hypertension and/or   │         │
│ hypertension and/or signs of severe decompensation │ severe decompensation (Child-Pugh score > 6)       │         │
│ of function (\> 6 points according to the Child-   │                                                    │         │
│ Pugh classification)                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are related to any of the on-site     │ Patient is related to the research staff of the    │      72 │
│ research personnel directly involved in the        │ clinical investigative site who are directly       │         │
│ conduct of the trial or are an immediate relative  │ involved in the trial or is the immediate family   │         │
│ of the study investigator. 'Immediate relative'    │ member of the investigator. The immediate family   │         │
│ means husband, wife, parent, son, daughter,        │ members include husband/wife, parents, children or │         │
│ brother, or sister (regardless of whether they are │ brothers (or sisters), regardless of whether they  │         │
│ natural or adopted)                                │ are natural or adopted                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who, from the investigator's point of     │ Patients who, from investigator's point of view,   │      79 │
│ view, will not comply with the observation         │ will fail to comply with the observation           │         │
│ requirements of the study or adhere to study drug  │ requirements of the trial or with the dosing       │         │
│ dosing regimens                                    │ regimen of the investigational drugs               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ H. pylori eradication within 2 months prior to     │ H. Pylori eradication within 2 months before study │      80 │
│ enrollment                                         │ entry                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Organic diseases of the gastrointestinal tract     │ Organic diseases of the digestive system (gastro-  │      81 │
│ (gastroesophageal reflux disease (GERD), peptic    │ oesophageal reflux disease (GERD), ulcer, chronic  │         │
│ ulcer, chronic pancreatitis, cholelithiasis,       │ pancreatitis, cholelithiasis, fatty liver disease, │         │
│ hepatosis, hepatitis, hepatic cirrhosis, etc.)     │ hepatitis, cirrhosis of liver, etc.)               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intestinal infection within 2 months prior to      │ Intestinal infection within 2 months before study  │      81 │
│ enrollment                                         │ entry                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Scheduled hospitalization during the study for any │ Planned hospitalization during the study period,   │      84 │
│ diagnostic or therapeutic procedures               │ for any diagnostic or treatment procedures         │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 75
Average Levenshtein Ratio of individual lines: 70.34883720930233
OverAll Ratio: 72.67441860465117
